SLC5A5 and thyroid cancer: Reduced histone acetylation in the NIS promoter has also been implicated in BRAFV600E-mediated NIS repression, corroborating the increment in NIS expression found in thyroid cancer cells treated with histone deacetylase inhibitors (HDACis) [110,111,112,113,114,115].